SCHEMBL3069366

SCHEMBL3069366

COC(=O)c1ccc(C2CCN(C(=O)OC(C)(C)C)CC2O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.46
KMT2A Q03164 1/20 0.46
USP30 Q70CQ3 1/20 0.45
GPR119 Q8TDV5 4/20 0.45
ALDH1A1 P00352 1/20 0.45
TACR1 P25103 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN6 P29350 1/20 0.44
ABL1 P00519 1/20 0.43
RIN1 Q13671 1/20 0.43
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43
NR1H2 P55055 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
NAMPT P43490 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24244951 1.00 PDE4B (0.46) PDE4BKMT2AUSP30GPR119ALDH1A1
SCHEMBL22551223 1.00 PDE4B (0.46) PDE4BKMT2AUSP30GPR119ALDH1A1
SCHEMBL31549592 0.93 KMT2A (0.48) PDE4BKMT2AGPR119ALDH1A1TP53
SCHEMBL30988622 0.91 PDE4B (0.46) PDE4BKMT2AUSP30GPR119ALDH1A1
SCHEMBL30988638 0.91 PDE4B (0.46) PDE4BKMT2AUSP30GPR119ALDH1A1
SCHEMBL31549608 0.91 PDE4B (0.46) PDE4BKMT2AUSP30GPR119ALDH1A1
SCHEMBL24244962 0.87 USP30 (0.47) PDE4BKMT2AUSP30GPR119ALDH1A1
SCHEMBL15961873 0.87 USP30 (0.47) PDE4BKMT2AUSP30GPR119ALDH1A1
SCHEMBL24244961 0.87 USP30 (0.47) PDE4BKMT2AUSP30GPR119ALDH1A1
SCHEMBL8194766 0.87 ALDH1A1 (0.57) PDE4BKMT2AGPR119ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001893-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2026-01-01 US disclosed
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2025-11-06 US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 US disclosed
US-20250320205-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 US disclosed
US-20250320206-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 US disclosed
EP-2960238-B1 MONOCYCLIC PYRIDINE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2017-04-05 EP disclosed
EP-2960238-A1 MONOCYCLIC PYRIDINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2015-12-30 EP disclosed
US-8933099-B2 Monocyclic pyridine derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-01-13 US disclosed
US-8933099-B2 Monocyclic pyridine derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-01-13 US disclosed
US-20140235614-A1 MONOCYCLIC PYRIDINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-08-21 US disclosed
US-20140235614-A1 MONOCYCLIC PYRIDINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-08-21 US disclosed
US-7842688-B2 Organic compounds NOVARTIS PHARMA AG (CH) 2010-11-30 US disclosed
US-7790715-B2 Organic compounds NOVARTIS AG (CH) 2010-09-07 US disclosed
US-20090012055-A1 Organic compounds HEROLD PETER 2009-01-08 US disclosed
EP-1961752-A2 Piperidine Compounds Speedel Experimenta AG (CH) 2008-08-27 EP disclosed
US-20070010511-A1 Organic compounds NOVARTIS PHARMA AG (CH) 2007-01-11 US disclosed
EP-1670760-A1 ORGANIC COMPOUNDS Speedel Experimenta AG (CH) 2006-06-21 EP disclosed
WO-2005061457-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012055-A1 Organic compounds REN, ACE, ACE2 PDE4B 312/4885KMT2A 3839/4885USP30 3872/4885
US-20070010511-A1 Organic compounds REN, ACE, ACE2 PDE4B 312/4885KMT2A 3839/4885USP30 3872/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 PDE4B 985/4885KMT2A 440/4885USP30 1139/4885
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, STAT1, STAT5B PDE4B 588/4885KMT2A 684/4885USP30 2781/4885
US-20140235614-A1 MONOCYCLIC PYRIDINE DERIVATIVE FGFR2, FGFR1, FGFR3 PDE4B 1813/4885KMT2A 1269/4885USP30 4797/4885
US-20260001893-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, NCOR1, NCOR2 PDE4B 1635/4885KMT2A 1551/4885USP30 3903/4885
US-20250320205-A1 STAT6 DEGRADERS STAT6, STAT1, STAT5B PDE4B 1119/4885KMT2A 396/4885USP30 1157/4885
US-20250320206-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 PDE4B 985/4885KMT2A 440/4885USP30 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.